CD1c+ restricted T cells exhibit potent anti-leukemia activity in mouse models, indicating that this lipid antigen may represent a new target for immunotherapy of hematological malignancies (Lepore et al., 2015). This evidence concerns the gene CD1C and hematologic disorder.